In a significant move to combat HIV in Africa, the United States has initiated the delivery of Lenacapavir, a revolutionary injectable treatment, to Eswatini and Zambia. This development comes despite President Donald Trump’s substantial reductions in global aid earlier this year. The initiative is a collaborative effort involving the Global Fund to Fight AIDS, Tuberculosis and Malaria, and Gilead Sciences, the pharmaceutical company behind the drug. Approximately 1,000 doses have already been dispatched, with administration set to commence this week, according to Peter Sands, Executive Director of the Global Fund. Jeremy Lewin, a State Department aid coordinator, revealed plans to fund two million doses for low- and middle-income African nations, aiming for completion by 2028, potentially as early as mid-2027. Lenacapavir, requiring only biannual administration, marks a significant advancement over daily pill regimens, offering a promising reduction in new HIV infections, particularly among pregnant and breastfeeding women. Despite the Trump administration’s drastic cuts to foreign aid and HIV/AIDS prevention programs, this initiative underscores a targeted approach to health assistance. Gilead Sciences’ Chairman and CEO, Daniel O’Day, highlighted the historic nature of this rollout, noting it as the first instance of a medication being introduced in Africa the same year it was approved in the US. However, this effort is shadowed by grim forecasts regarding the impact of reduced global aid, with experts predicting an additional 22.6 million preventable deaths by 2030 due to aid cuts by the US and European countries.